Suleiman G, Suleiman J, Suleiman S, Castro I, Ferreira Junior O; International Conference on AIDS.
Int Conf AIDS. 1994 Aug 7-12; 10: 207 (abstract no. PB0257).
Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil.
In this ongoing study, 34 patients with HIV infection and CD4 counts > 100 < 500 mega/l were admited from February 1993 through April 1993. Its objective is to evaluate the safety of ddI 200 mg administered on a b.i.d. regimen (every 12 hours) plus ZDV 100 mg administered t.i.d. (every 8 hours) for a one year period. There were 16 males and 18 females in the study with age ranging from 21 to 52 (average 36.5 years old). Four patients refused to receive treatment for personal reasons and were withdrawn from the study. For all 34 patients, median baseline CD4 counts at study entry was 363 +/- 82 (range 179 to 500). On the nineth month of treatment for 24 patients analysed CD4 median count was 513 +/- 162 (range 159 to 898), p < 0.0001. Until the present date none of the 30 patients involved in the study has presented any opportunistic infection. In the evaluation of hematologic an biochemistry parameters it has been observed that hemoglobin, red blood cell, neutrophils an platelets counts, as well as potassium, glucose, BUN, serum creatinine, ureia acid have maintained baseline levels. Hyperamilasemia was observed in 7 of the 30 patients, with no clinical signs. Severe hipocalcemia was observed in 1 (30 patients). Preliminary analysis of this study demonstrates that the combination of ddI and ZDV at the above mentioned is safe to be administered to HIV+ patients with CD4 counts > 100 < 500 mega/l, and it seems to delay opportunistic infections in this patients group.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antigens, CD4
- CD4 Lymphocyte Count
- CD4-Positive T-Lymphocytes
- Didanosine
- Drug Therapy, Combination
- Female
- HIV Infections
- HIV Seropositivity
- Humans
- Male
- Zidovudine
- drug therapy
- immunology
- therapy
Other ID:
UI: 102208536
From Meeting Abstracts